Table 3.

Detailed Evaluation Regarding Main Features of Both MTX-Autoinjectors After Cross-Testing

		Surveyed MTX-Autoinjector
Characteristics	Score	A (n=65)	B (n=35)
Relative satisfaction	1	9%	51%
	2	14%	20%
	3	77%	29%
Easy to use (injection)	1	9%	46%
	2	16%	31%
	3	75%	23%
Easy to uncap	1	10%	6%
	2	45%	63%
	3	45%	31%
Easy to grip	1	11%	15%
	2	30%	42%
	3	59%	43%
Injection mode (± push button)	1	9%	51%
	2	11%	17%
	3	80%	31%
Convenient (size, format)	1	3%	46%
	2	33%	29%
	3	64%	26%
Design (size, ergonomics)	1	12%	54%
	2	16%	26%
	3	72%	20%
Adapted to the administration of the treatment	1	3%	23%
	2	44%	54%
	3	53%	23%
Means of identification of different dosages	1	2%	14%
	2	47%	71%
	3	51%	14%
End-of-injection recognition system	1	6%	60%
	2	31%	31%
	3	63%	9%

Notes: Figures are rounded at the nearest unit. Surveyed MTX-autoinjector: A (n=65), the 65 RA patients who currently used MTX-autoinjector B evaluated MTX-autoinjector A (unfamiliar MTX-autoinjector); B (n=35), the 35 RA patients who currently used MTX-autoinjector A evaluated MTX-autoinjector B (unfamiliar MTX-autoinjector). 1 = Worse than the familiar MTX-autoinjector; 2 = Similar to the familiar MTX-autoinjector; 3 = Better than the familiar MTX-autoinjector.

Abbreviation: MTX, methotrexate.